Claude AI designed protein binders against scorpion neurotoxins

AI Designs Protein Binders for Scorpion Neurotoxins

An internal research model of Claude AI, operating within Claude Science, designed protein minibinders targeting scorpion neurotoxins. This initiative was a collaboration with Citrini Research, exploring AI's role in accelerating drug discovery.

The project focused on addressing scorpion envenomation, a neglected tropical disease affecting over 1.2 million people annually and causing more than 3,250 deaths, primarily among children.

Design and Testing Process

Claude generated 318,484 protein designs and selected 180 for testing. The research team added 31 more designs with Claude's assistance, totaling 211 designs.

Partners Adaptyv Bio and Twist Bioscience, both contract research organizations, experimentally tested all 211 designs. Of these, 17 designs met the criteria for binding to one of four dangerous scorpion neurotoxins.

Implications for Drug Discovery

This experiment demonstrates AI's capability to contribute to the design phase of drug discovery, particularly for conditions that receive limited investment due to high development costs and low commercial returns.

The successful identification of binding proteins suggests a pathway for developing new treatments, such as scorpion antivenom, more efficiently. All 211 designs and their experimental data have been released as a resource for the scientific community.